Insider · CIK 0001807831
Nathan D. Weaver
officer
Files at FUL (FULLER H B CO). First filing Nov 14, 2025, latest Nov 14, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 1
$0 bought, $413k sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
FUL: FULLER H B CO
FULOct 9, 2026 · close 49.56
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 26Weak | FULsell FULLER H B CO | $413k 7,075 shares | -43% | +23% from low-24% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 27, 2026 | FUL FULLER H B CO | MOption exercise Common Stock | +870 | $59.81 | $52k | 12,007 | Jan 29, 2026 |
| Jan 27, 2026 | FUL FULLER H B CO | FTax withholding Common Stock | -268 | $59.81 | $16k | 11,739 | Jan 29, 2026 |
| Jan 27, 2026 | FUL FULLER H B CO | MOption exercise Restricted Stock Unitsderivative | -870 | $59.81 | $52k | 1,770 | Jan 29, 2026 |
| Jan 26, 2026 | FUL FULLER H B CO | MOption exercise Common Stock | +555 | $60.07 | $33k | 11,329 | Jan 28, 2026 |
| Jan 26, 2026 | FUL FULLER H B CO | FTax withholding Common Stock | -192 | $60.07 | $12k | 11,137 | Jan 28, 2026 |
| Jan 26, 2026 | FUL FULLER H B CO | AGrant or award Employee Stock Option (Right-to-Buy)derivative | +23,187 | $59.81 | $1.4M | 23,187 | Jan 28, 2026 |
| Jan 26, 2026 | FUL FULLER H B CO | MOption exercise Restricted Stock Unitsderivative | -555 | $60.07 | $33k | 574 | Jan 28, 2026 |
| Jan 26, 2026 | FUL FULLER H B CO | AGrant or award Restricted Stock Unitsderivative | +3,420 | $0.00 | $0 | 3,420 | Jan 28, 2026 |
| Jan 24, 2026 | FUL FULLER H B CO | MOption exercise Common Stock | +1,271 | $60.07 | $76k | 10,823 | Jan 27, 2026 |
| Jan 24, 2026 | FUL FULLER H B CO | MOption exercise Common Stock | +562 | $60.07 | $34k | 11,385 | Jan 27, 2026 |
| Jan 24, 2026 | FUL FULLER H B CO | AGrant or award Common Stock | +50 | $60.07 | $3,004 | 11,435 | Jan 27, 2026 |
| Jan 24, 2026 | FUL FULLER H B CO | FTax withholding Common Stock | -198 | $60.07 | $12k | 11,237 | Jan 27, 2026 |
| Jan 24, 2026 | FUL FULLER H B CO | FTax withholding Common Stock | -463 | $60.07 | $28k | 10,774 | Jan 27, 2026 |
| Jan 24, 2026 | FUL FULLER H B CO | MOption exercise Performance Stock Unitsderivative | -1,271 | $60.07 | $76k | 0 | Jan 27, 2026 |
| Jan 24, 2026 | FUL FULLER H B CO | MOption exercise Restricted Stock Unitsderivative | -562 | $60.07 | $34k | 0 | Jan 27, 2026 |
| Jan 20, 2026 | FUL FULLER H B CO | AGrant or award Performance Stock Unitsderivative | +1,271 | $0.00 | $0 | 1,271 | Jan 22, 2026 |
| Nov 13, 2025 | FUL FULLER H B CO | MOption exercise Common Stock | +9,546 | $33.38 | $319k | 16,516 | Nov 14, 2025 |
| Nov 13, 2025 | FUL FULLER H B CO | SOpen-market sale Common Stock | -7,075 | $58.38 | $413k | 9,441 | Nov 14, 2025 |
| Nov 13, 2025 | FUL FULLER H B CO | MOption exercise Employee Stock Option (Right-to-Buy)derivative | -9,546 | $33.38 | $319k | 0 | Nov 14, 2025 |
| Aug 5, 2025 | FUL FULLER H B CO | IDiscretionary transaction Common Stockindirect: By 401(k) Plan | -213 | $56.84 | $12k | 0 | Aug 7, 2025 |
| Jan 31, 2025 | FUL FULLER H B CO | MOption exercise Common Stock | +328 | $63.13 | $21k | 7,058 | Feb 4, 2025 |
| Jan 31, 2025 | FUL FULLER H B CO | FTax withholding Common Stock | -88 | $63.13 | $5,555 | 6,970 | Feb 4, 2025 |
| Jan 31, 2025 | FUL FULLER H B CO | MOption exercise Phantom Unitsderivative | -328 | $63.13 | $21k | 5,803 | Feb 4, 2025 |
| Jan 27, 2025 | FUL FULLER H B CO | AGrant or award Employee Stock Option (Right-to-Buy)derivative | +14,844 | $64.28 | $954k | 14,844 | Jan 29, 2025 |
| Jan 27, 2025 | FUL FULLER H B CO | AGrant or award Restricted Stock Unitsderivative | +2,599 | $0.00 | $0 | 2,599 | Jan 29, 2025 |
| Jan 24, 2025 | FUL FULLER H B CO | MOption exercise Common Stock | +1,315 | $62.32 | $82k | 6,159 | Jan 28, 2025 |
| Jan 24, 2025 | FUL FULLER H B CO | MOption exercise Common Stock | +537 | $62.32 | $33k | 6,696 | Jan 28, 2025 |
| Jan 24, 2025 | FUL FULLER H B CO | MOption exercise Common Stock | +421 | $62.32 | $26k | 7,117 | Jan 28, 2025 |
| Jan 24, 2025 | FUL FULLER H B CO | AGrant or award Common Stock | +45 | $62.32 | $2,804 | 7,162 | Jan 28, 2025 |
| Jan 24, 2025 | FUL FULLER H B CO | FTax withholding Common Stock | -150 | $62.32 | $9,348 | 7,012 | Jan 28, 2025 |
| Jan 24, 2025 | FUL FULLER H B CO | FTax withholding Common Stock | -187 | $62.32 | $12k | 6,825 | Jan 28, 2025 |
| Jan 24, 2025 | FUL FULLER H B CO | FTax withholding Common Stock | -482 | $62.32 | $30k | 6,343 | Jan 28, 2025 |
| Jan 26, 2025 | FUL FULLER H B CO | MOption exercise Common Stock | +547 | $62.77 | $34k | 6,890 | Jan 28, 2025 |
| Jan 26, 2025 | FUL FULLER H B CO | FTax withholding Common Stock | -160 | $62.77 | $10k | 6,730 | Jan 28, 2025 |
| Jan 24, 2025 | FUL FULLER H B CO | MOption exercise Performance Stock Unitsderivative | -1,315 | $62.32 | $82k | 0 | Jan 28, 2025 |
| Jan 24, 2025 | FUL FULLER H B CO | MOption exercise Restricted Stock Unitsderivative | -421 | $62.32 | $26k | 0 | Jan 28, 2025 |
| Jan 24, 2025 | FUL FULLER H B CO | MOption exercise Restricted Stock Unitsderivative | -537 | $62.32 | $33k | 554 | Jan 28, 2025 |
| Jan 26, 2025 | FUL FULLER H B CO | MOption exercise Restricted Stock Unitsderivative | -547 | $62.77 | $34k | 1,112 | Jan 28, 2025 |
| Jan 22, 2025 | FUL FULLER H B CO | AGrant or award Performance Stock Unitsderivative | +1,315 | $0.00 | $0 | 1,315 | Jan 23, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.